Anoro Ellipta is a combination inhaler containing umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA) [1]. It is prescribed for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema [1]. The medication is not indicated for relief of acute bronchospasm or for asthma [1].
How does Anoro Ellipta work for COPD?
Anoro Ellipta functions by relaxing the muscles in the airways, making it easier to breathe [1]. Umeclidinium works by blocking the action of acetylcholine on muscarinic receptors in the airways, leading to bronchodilation. Vilanterol stimulates beta2-adrenergic receptors in the smooth muscle of the airways, also resulting in bronchodilation [1]. The dual action of these two components aims to provide sustained relief from COPD symptoms.
When was Anoro Ellipta approved?
Anoro Ellipta was approved by the U.S. Food and Drug Administration (FDA) in December 2013 [2].
What are the main side effects of Anoro Ellipta?
Common side effects associated with Anoro Ellipta include nasopharyngitis (cold-like symptoms), diarrhea, pain in the extremities, chest pain, and potentially atrial fibrillation, a type of irregular heartbeat [1]. Patients should report any new or worsening symptoms to their healthcare provider [1].
What are the risks associated with Anoro Ellipta?
Anoro Ellipta carries risks that patients should be aware of. These include an increased risk of asthma-related deaths when used in patients with asthma, paradoxically worsening bronchospasm, cardiovascular effects such as increased blood pressure and heart rate, and potential for hypersensitivity reactions [1]. It is also associated with urinary retention and acute angle glaucoma [1].
How long does Anoro Ellipta provide symptom relief?
Anoro Ellipta is designed for long-term maintenance treatment and provides 24-hour bronchodilation with a single daily dose [1]. This sustained action helps manage daily symptoms of COPD.
Are there alternatives to Anoro Ellipta for COPD treatment?
Yes, several alternative treatments exist for COPD, including other LAMAs, LABAs, or combination inhalers containing different active ingredients [3]. Inhaled corticosteroids (ICS) are also used, often in combination with LABAs or LAMAs, particularly for patients with a history of exacerbations or eosinophilic inflammation [3]. The choice of treatment depends on individual patient needs, symptom severity, and response to therapy.
What is the patent status of Anoro Ellipta?
The patent landscape for Anoro Ellipta, like other branded medications, is complex and involves multiple patents covering its composition of matter, methods of use, and manufacturing [4]. DrugPatentWatch.com tracks these patents, providing detailed information on their expiry dates and potential for generic entry [4]. Patents for Anoro Ellipta are in effect, and their expiry will determine when generic versions can become available.
How does Anoro Ellipta compare to other COPD inhalers?
Anoro Ellipta is a LAMA/LABA combination. Other COPD inhalers include single-agent LAMAs (like tiotropium), single-agent LABAs (like salmeterol), ICS/LABA combinations (like Symbicort or Advair), and triple therapy combinations (ICS/LAMA/LABA) [3]. The choice among these depends on the patient's specific COPD profile and treatment goals.
What is the price of Anoro Ellipta?
The price of Anoro Ellipta can vary significantly depending on insurance coverage, pharmacy, and location. Pharmaceutical companies often offer patient assistance programs to help eligible individuals with the cost of their medications [5].
Sources:
1. Anoro Ellipta Prescribing Information.
2. U.S. Food and Drug Administration (FDA) approvals database.
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
4. DrugPatentWatch.com.
5. Manufacturer's patient assistance program information.